The Law Office of Abe Shainberg is investigating the Board of Directors of ZymoGenetics, Inc. (“ZymoGenetics” or the “Company”) (NasdaqGM: ZGEN) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to Bristol-Myers Squibb Co. ("Bristol-Myers Squibb") (NYSE: BMY). Under the terms of the transaction, ZymoGenetics shareholders will receive $9.75 in cash for each share of ZymoGenetics common stock they own for a total transaction value of approximately $885 million.

The investigation concerns whether the ZymoGenetics Board of Directors breached their fiduciary duties to ZymoGenetics stockholders by failing to adequately shop the Company before entering into this transaction and whether Bristol-Meyers Squibb is underpaying for ZymoGenetics shares, thus unlawfully harming ZymoGenetics stockholders.

If you own common stock in ZymoGenetics and wish to obtain additional information, contact Abe Shainberg, Esq. either via email at as@ashainberglaw.com or by telephone at (212) 425-7286, or visit http://www.ashainberglaw.com/zymogenetics-zgen.html.

Mr. Shainberg has expertise in prosecuting investor securities litigation, is a certified and registered arbitrator and mediator involving financial matters, and represents investors in various matters nationwide.

Copyright Business Wire 2010